Inhibikase Therapeutics Inc

NASDAQ:IKT   9:43:10 AM EDT
1.60
-0.05 (-3.03%)
Earnings Announcements

Inhibikase Therapeutics Reports Q3 Loss Per Share Of $0.18

Published: 11/15/2021 23:14 GMT
Inhibikase Therapeutics Inc (IKT) - Inhibikase Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Period Activity.
Q3 Loss per Share $0.18.
Revenue is expected to be $0.3 Million
Adjusted EPS is expected to be -$0.17

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be $0.00

More details on our Analysts Page.